Efficacy, Safety, and Biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma

Oncologist

Volumn 17, Issue 8, 2012, Pages 1063-1072

  Boige, Valérie ^a   Malka, David ^a   Bourredjem, Abderrahmane ^a   Dromain, Clarisse ^a   Baey, Charlotte ^a   Jacques, Nathalie ^a   Pignon, Jean Pierre ^a   Vimond, Nadege ^a   Bouvet Forteau, Nathalie ^a   De Baere, Thierry ^a   Ducreux, Michel ^a   Faraced, Françoise ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bevacizumab; Biomarker; Circulating endothelial cells; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENIC FACTOR; BEVACIZUMAB; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; PROPRANOLOL; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; ESOPHAGUS VARICES; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE TEST; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TUMOR BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; SAFETY;

EID: 84865208483     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0465     Document Type: Article

References (54)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
2. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
3. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547.
4. Pang R, Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006;242:151-167.
5. Tseng PL, Tai MH, Huang CC et al. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol 2008;98:349-357.
6. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
7. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
8. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004;350: 2335-2342.
10. Sandler A, Gray R, Perry MC et al. Paclitaxelcarboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006;355:2542-2550.
11. Finn RS, Bentley G, Britten CD et al. Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model. Liver Int 2009;29:284-290.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
13. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
14. Jacques N, Vimond N, Conforti R et al. Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods 2008;337:132-143.
15. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
16. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
17. Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800.
18. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903.
19. Sun W, Sohal D, Haller DG et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011;117:3187-3192. doi: 10.1002/cncr.25889.
20. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-850.
21. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998.
22. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981-986.
23. Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009;27:3027-3035.
24. Burroughs AK, Patch D. Primary prevention of bleeding from esophageal varices. N Engl J Med 1999;340:1033-1035.
25. Bornman PC, Krige JE, Terblanche J. Management of oesophageal varices. Lancet 1994;343:1079-1084.
26. Llovet JM, Di Bisceglie AM, Bruix J et al.; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
27. Park JW, Finn RS, Kim JS et al. Phase II, openlabel study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-1983.
28. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
29. Lassau N, Koscielny S, Chami L et al. Advanced hepatocellular carcinoma: Early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification-preliminary results. Radiology 2011;258:291-300.
30. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-1183.
31. Blann AD, Woywodt A, Bertolini F et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005:93;228-235.
32. Goon PK, Lip GY, Boss CJ et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006;8:79-88.
33. Taylor M, Rössler J, Geoerger B et al. High levels of circulating VEGFR2 bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 2009;15:4561-4571.
34. Jubb AM, Oates AJ, Holden S et al. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-635.
35. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009;27: 3020-3026.
36. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010;21:1765-1771.
37. Malka D, Boige V, Jacques N et al. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol 2012;23:919-927.
38. Mancuso P, Colleoni M, Calleri A et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-459.
39. Dellapasqua S, Bertolini F, Bagnardi V et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-4905.
40. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
41. Miles DW, de Haas SL, Dirix L et al. Plasma biomarker analyses in the AVADO phase III randomized study of first-line bevacizumab docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer [abstract P2-16-04]. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
42. Kaseb AO, Morris JS, Hassan MM et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-3899.
43. Sessa C, Guibal A, Del Conte G et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: Tools or decorations? Nat Clin Pract Oncol 2008;5:378-391.
44. Shao YY, Lin ZZ, Hsu C et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 2012;82:59-66.
45. Miyahara K, Nouso K, Tomoda T et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2011;26:1604-1611.
46. Porta C, De Amici M, Quaglini S et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008;19:353-358.
47. Wong VW, Yu J, Cheng AS et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-2770.
48. Parasole R, Izzo F, Perrone F et al. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res 2001;7:3504-3509.
49. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
50. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741.
51. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-1071.
52. Baar J, Silverman P, Lyons J et al. A vasculaturetargeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: Impact on angiogenic biomarkers. Clin Cancer Res 2009;15:3583-3590.
53. Jubb AM, Miller KD, Rugo HS et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:372-381.
54. Cheng A, Kang Y, Lin D et al. Phase III trial of sunitinib versus sorafenib in advanced hepatocellular carcinoma [abstract 4000]. J Clin Oncol 2011;29(No 15 suppl):256S.